ACTRN12621001442897
Completed
未知
Randomised Controlled Trial of a Standard Cognitive Behavioural Treatment versus Augmented Cognitive Behavioural Treatment on PTSD and Depression in Emergency Service Personnel
SW Sydney0 sites100 target enrollmentOctober 25, 2021
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Posttraumatic stress disorder
- Sponsor
- SW Sydney
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Meet criteria for PTSD as defined by DSM\-5
- •Aged at least 18 years
- •Current or former member of Emergency Service Personnel
- •Sufficient English proficiency
Exclusion Criteria
- •Current psychosis
- •Imminent suicidal risk
- •Current substance dependence
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A phase 3 study of parsaclisib plus ruxolitinib in patients with myelofibrosismyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-003415-98-HUIncyte Corporation212
Active, not recruiting
Phase 1
An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Heterozygous Familial HypercholesterolemiaEUCTR2017-001903-60-DESanofi-aventis recherche & développement500
Active, not recruiting
Phase 1
A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar I Disorder, with Open-Label ExtensioBIPOLAR MANIAEUCTR2004-003781-14-ESJohnson and Johnson Pharmaceutical Research and Development, una división de Janssen-Cilag, S.A
Active, not recruiting
Phase 1
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)Extensive Stage Small Cell Lung Cancer (ED SCLC)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-003503-64-GBAbbvie Deutschland GmbH & Co. KG748
Active, not recruiting
Not Applicable
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT 126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsAlzheimer's DiseaseMedDRA version: 15.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2011-004849-40-DEAbbVie Deutschland GmbH & Co. KG420